PERKINELMER INC Stock Price, News & Analysis

Revvity (NYSE: RVTY) has launched three new Mimix IVD reference standards designed for monitoring next-generation sequencing and ddPCR assays in oncology diagnostic testing. These cell line-derived standards, developed under FDA regulatory requirements, help laboratories monitor test performance, assess assay variation, and identify errors in genomic DNA testing workflows. The products include Mimix OncoSpan FFPE Reference Standard IVD, Mimix OncoSpan gDNA Reference Standard IVD, and Mimix Myeloid Cancer Panel gDNA Reference Standard IVD. Drawing on 14 years of experience in oncology reference standards, Revvity's Mimix controls use human cell lines instead of synthetic sources to better replicate patient samples and maintain genomic complexity.

Revvity (NYSE: RVTY) has launched the new IDS i20™ analytical platform through EUROIMMUN, offering fully automated processing of chemiluminescence immunoassays (ChLIA). The CE marked and FDA listed device enables labs to consolidate multiple specialty tests on a single instrument, processing up to 140 tests per hour. The platform can simultaneously run 20 analytes from six diagnostic specialties including endocrinology, allergy, autoimmune and infectious diseases, Alzheimer's disease, and therapeutic drug monitoring. Key features include continuous loading of samples, integrated cooling of reagents, and state-of-the-art software with enhanced cybersecurity and usability standards.

Revvity (NYSE: RVTY) has announced its participation in two major upcoming healthcare investor conferences. The company will be represented at the Bank of America Global Healthcare Conference 2025 on May 13, where CFO Max Krakowiak will speak at 9:20 a.m. PT.

Additionally, President and CEO Prahlad Singh will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 8:00 a.m. ET. Both presentations will be conducted as fireside chats, providing updates on the company and its strategic priorities.

Investors can access live audio webcasts through the Events section of Revvity's website. Recorded replays will be available on the company's Investor Relations website for a minimum of 30 days following the events.

Revvity (NYSE: RVTY) reported strong Q1 2025 financial results with revenue reaching $665 million, representing 2% reported growth and 4% organic growth. The company's GAAP EPS increased to $0.35 from $0.21 year-over-year, while adjusted EPS from continuing operations reached $1.01.

By segment, Life Sciences revenue grew 1% to $340 million with 2% organic growth and improved adjusted operating margin to 31.1%. Diagnostics revenue increased 3% to $324 million with 5% organic growth, though adjusted operating margin decreased to 22.8%.

The company reaffirmed its full-year 2025 organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00, while raising its revenue guidance to $2.83-$2.87 billion due to foreign currency exchange rate changes.

Revvity (NYSE: RVTY) has announced its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on August 8, 2025 to shareholders of record as of the close of business on July 18, 2025.

Revvity (NYSE: RVTY) has scheduled its first quarter 2025 financial results announcement for Monday, April 28, 2025, before market open. The company will hold a conference call at 8:00 a.m. ET on the same day to discuss the results. CEO Prahlad Singh and CFO Max Krakowiak will host the call, which will be accessible via live audio webcast through the Investors section of Revvity's website.

Revvity (NYSE: RVTY) has received FDA approval for its Auto-Pure 2400 liquid handling platform integrated with the T-SPOT.TB test for latent tuberculosis detection. The system, which was initially launched outside the U.S. in 2024, combines automation with high clinical accuracy in TB diagnostics.

The Auto-Pure 2400 platform features automated liquid handling and magnetic cell isolation technology, processing up to 24 samples per run and completing Day 1 testing in under 3.5 hours with minimal user interaction. The T-SPOT.TB test, recognized by WHO as the only ELISPOT-based IGRA, includes a cell number normalization step that ensures consistent results by reducing pre-analytical variables.

Key advantages include fewer indeterminate results, reduced repeat testing requirements, and reliable performance in immunocompromised patients.

Revvity (NYSE: RVTY) has expanded its partnership with Genomics England for the Generation Study, adding DNA sequencing services to their existing DNA extraction services. The collaboration aims to screen up to 100,000 newborns for over 200 rare genetic disorders through whole genome sequencing (WGS).

The company will provide an integrated end-to-end solution with a localized lab facility, enabling faster extraction and sequencing services. This research project, conducted in partnership with the National Health Service, will help inform future decisions on implementing WGS in newborn screening programs, potentially enabling earlier interventions and personalized care for pediatric-onset conditions.

Revvity (NYSE: RVTY) has announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG), expanding its infectious disease diagnostics portfolio. This novel assay is designed to support measles virus infection diagnosis and immune status determination.

The test is notable as the first commercial assay validated for dried blood spots (DBS) alongside traditional serum and plasma samples. DBS testing requires only fingertip blood droplets on paper cards, offering advantages in routine testing, studies, and regions with medical infrastructure.

The assay addresses a market gap as the first commercial solution for detecting anti-measles virus IgG antibodies using DBS samples, eliminating the need for laboratories to conduct their own validations. The test can be processed both manually and automatically using EUROIMMUN's scalable solutions.